Project Grant K22AI187413
Award Date
6/18/25
Completion Date
5/31/27
Dollars Obligated
$162K
Federal Agency
National Institute of Allergy and Infectious Diseases
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Indianapolis, IN 46202, USA
Similar Awards
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $586,250 to the University of Massachusetts Medical School (UMass Medical) to elucidate the pathways that lead to the differentiation of TFH13 cells, a novel T cell subset that drives the production of high-affinity, pathogenic IgE antibodies in allergic diseases. The overarching goal is to determine the distinct...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $612,328 to National Jewish Health to conduct research investigating how the transcription factor MITF regulates mast cell lineage commitment and function. The research aims to enhance understanding of the regulation of mast cell genes that influence allergy susceptibility and severity. Specifically, the grant will...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $417,984 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the Scripps Research Institute in La Jolla, California. The grant, awarded on March 7, 2025, will support research to identify actionable targets for the selective induction of regulatory T cell (Treg) differentiation. The research aims to address a key knowledge gap in understanding the biology and application of naive CD4...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), will provide $917,375 to Brigham & Women's Hospital Inc. to conduct research on defining the heterogeneous effector function of human mast cell subsets. The research aims to comprehensively characterize the cytokine, chemokine, and growth factor production profiles of in vitro-derived mast cell subtypes (MCT and...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) provides $175,000.00 to the La Jolla Institute for Immunology to conduct research on the role of Alternaria fungal sensitization in asthma pathogenesis. The key research objectives are to: Determine the association between Alternaria-specific T cell subsets, including a novel "THIFNR" cell population, and protection...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $300,000 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Cellergy Pharma Inc. in Wilmington, Delaware. The goal of this 2-year project (Feb 2025 - Jan 2027) is to develop an innovative antibody drug that can efficiently and specifically eliminate IgE-producing B cells to achieve complete and durable suppression of allergic symptoms. The project will determine the potency of the...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $320,863 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Aaiit LLC, a minority-owned for-profit company doing business as Inflammation Immuno Therapy, to develop a bifunctional IgE antagonist and dissociator (ANDI) drug. The ANDI drug is intended to improve lung function and reduce asthmatic exacerbations in patients with severe allergic asthma by removing IgE bound to mast...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) supports research into the role of immunoglobulin E (IgE) and the sugar-binding protein galectin-3 in the activation of basophils, which play a key role in allergic reactions. The $162,728 award, granted to The Johns Hopkins University, aims to investigate the mechanisms by which galectin-3 can activate basophils independently of allergen...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $242,310 to Yale University to conduct research focused on elucidating the cellular and molecular mechanisms governing the catabolism (breakdown) of the antibody isotype IgE. The research aims to uncover the receptors and cell types responsible for IgE clearance, as well as characterize the impact of IgE...
This Project Grant award, valued at $194,740, was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The funding supports research to characterize the development of lung-resident, self-antigen-specific regulatory T cells (Tregs) following acute lung injury, with the goal of understanding how these "experienced" Tregs can promote tolerance and prevent future lung disease. The...